Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Combination therapy with angiotensin-converting-enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) decreases proteinuria; however, its safety and effect on the progression of kidney disease are uncertain. Methods We provided losartan (at a dose of 100 mg per day) to patients with type 2 diabetes, a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 300, and an estimated glomerular filtration rate (GFR) of 30.0 to 89.9 ml per minute per 1.73 m(2) of body-surface area and then randomly assigned them to receive lisinopril (at a dose of 10 to 40 mg per day) or placebo. The primary end point was the first occurrence of a change in the estimated GFR (a decline of ≥ 30 ml per minute per 1.73 m(2) if the initial estimated GFR was ≥ 60 ml per minute per 1.73 m(2) or a decline of ≥ 50% if the initial estimated GFR was <60 ml per minute per 1.73 m(2)), end-stage renal disease (ESRD), or death. The secondary renal end point was the first occurrence of a decline in the estimated GFR or ESRD. Safety outcomes included mortality, hyperkalemia, and acute kidney injury. Results The study was stopped early owing to safety concerns. Among 1448 randomly assigned patients with a median follow-up of 2.2 years, there were 152 primary end-point events in the monotherapy group and 132 in the combination-therapy group (hazard ratio with combination therapy, 0.88; 95% confidence interval [CI], 0.70 to 1.12; P=0.30). A trend toward a benefit from combination therapy with respect to the secondary end point (hazard ratio, 0.78; 95% CI, 0.58 to 1.05; P=0.10) decreased with time (P=0.02 for nonproportionality). There was no benefit with respect to mortality (hazard ratio for death, 1.04; 95% CI, 0.73 to 1.49; P=0.75) or cardiovascular events. Combination therapy increased the risk of hyperkalemia (6.3 events per 100 person-years, vs. 2.6 events per 100 person-years with monotherapy; P<0.001) and acute kidney injury (12.2 vs. 6.7 events per 100 person-years, P<0.001). Conclusions Combination therapy with an ACE inhibitor and an ARB was associated with an increased risk of adverse events among patients with diabetic nephropathy. (Funded by the Cooperative Studies Program of the Department of Veterans Affairs Office of Research and Development; VA NEPHRON-D ClinicalTrials.gov number, NCT00555217.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Given that diastolic heart disease develops early in T2D and the renin-angiotensin-aldosterone system (RAAS) plays a critical role in the pathophysiology of HF, the use of an ACE inhibitor or ARBs could be considered early in the treatment of hypertension, before the diagnosis of HF.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [260]
In the citing paper
“Two clinical trials studied the combinations of ACE inhibitors and ARBs and found no benefits on CVD or CKD, and the medication combination had higher adverse event rates (hyperkalemia and/or AKI) (87,88).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [88]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [85]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589
Cardiorenal end points in a trial of aliskiren for type 2 diabetes
Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1208799 · Cited by 1,319
Clinical Physiology of Acid-Base and Electrolyte Disorders
(1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-2-176_8 · Cited by 1,156
de Zeeuw, D., Remuzzi, G., Parving, H.-H., Keane, W. F., Zhang, Z., Shahinfar, S., Snapinn, S., Cooper, M. E., Mitch, W. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00653.x · Cited by 975
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910
Research works printed but not linked: 2
- National Kidney Foundation, 2002, Am J Kidney Dis, 30, S1
- International Conference on Harmonisation, 1995, Fed Regist, 60, 11284
Cited by
Items 901–1,000 of 1,001
Prevalence of coronary risk factors in load transport drivers
Braga, B. B., Ferreira, F. G., Reis, H. H. T., & Marins, J. C. B. (2022) · Revista Brasileira de Medicina do Trabalho · doi:10.47626/1679-4435-2022-695 · Cited by 2
Diabetic Kidney Care Redefined with a New Way into Remission
Hammad, N., Hassanein, M., & Rahman, M. U. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.08.002 · Cited by 3
Treating chronic kidney disease to reduce cardiovascular risk
Cice, G., Monzo, L., & Calò, L. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad067 · Cited by 2
Tantisattamo, E., & Kalantar‐Zadeh, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00002-5 · Cited by 4
Campbell, H. M., Murata, A. E., Henrie, A. M., & Conner, T. A. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.10.009 · Cited by 2
Self-citationAntihypertensive Drugs, Hypotension, and Ischemic Colitis
Blin, P. (2015) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0112-9 · Cited by 2
Ewen, S., & Böhm, M. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv033 · Cited by 2
Change in albuminuria as a surrogate endpoint in chronic kidney disease
Zhao, H., Lu, Y., & Ling, W. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30085-3 · Cited by 2
Change in albuminuria as a surrogate endpoint in chronic kidney disease
Pyne, L., Guyatt, G. H., & Walsh, M. W. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30089-0 · Cited by 2
Hormones Related to the Kidney and Cardiovascular System
Norman, A. W., & Henry, H. L. (2014) · Elsevier eBooks · doi:10.1016/b978-0-08-091906-5.00015-x · Cited by 1
Modern aspects of the treatment of patients with arterial hypertension and coronary heart disease
Бондарчук, С. А., & Andrievsky, О. G. (2020) · Medicine of Ukraine · doi:10.37987/1997-9894.2020.1(237).214171 · Cited by 1
Winchester, J. F., Charen, E., Ornillo, C., Sheth, N., & Harbord, N. B. (2015) · Springer eBooks · doi:10.1007/978-3-319-20797-1_22-1 · Cited by 1
Angiotensinogen and Risk of Stroke Events in Patients with Type 2 Diabetes Mellitus
Liu, T., & Liu, W. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s335746 · Cited by 1
Wang, Y., Ren, Q., Luo, H., Chen, G., Zhao, B., & Li, X. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2404107 · Cited by 1
Garza-García, C. A., Abraham, V. S., & Rovalo, M. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_55 · Cited by 1
Albuminuria and cardiovascular risk
Rigo, D., Jimenez, P. M., & Orías, M. (2023) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2023.03.003 · Cited by 1
Mei, M., Zeng, J., Fang, L., Xiang, S., Sun, H., Wen, C., Chai, L., Chen, X., Li, Z., Li, N., et al. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-04156-9 · Cited by 1
McEvoy, J. W., McCarthy, C. P., Brouwers, S., & Others, A. (2025) · HYPERTENSION · doi:10.22141/2224-1485.17.4.2024.372 · Cited by 2
Can we slow down the decline in renal function?
Cice, G., & Calò, L. (2024) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae123 · Cited by 1
Hypertension in People with Diabetic and Chronic Kidney Disease, Obesity, and Renin Secreting Tumors
Khan, S. H., & Weir, M. R. (2025) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-81292-7_3 · Cited by 2
Edith, L. E. L., García, M. A. O., Delgadillo‐Guzmán, D., Maldonado, I. C., & Aispuro, C. E. C. (2025) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2025.05.006 · Cited by 2
Li, A., Wei, M., Wu, C., Yin, D., Tang, Y.-T., Jiang, Y., Wang, C., Guo, J., Sun, A., Gu, X., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1543275 · Cited by 1
Lin, M., Zhang, H., Wu, H., Zhao, D., Nan, Z., & Fu, Y. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1657274 · Cited by 1
Sison, J., Jimeno, C., Matawaran, B. J., Ang, I. C. V., & Gonzales, E. M. (2021) · Philippine Journal of Internal Medicine · doi:10.65564/pjim.ae40192771 · Cited by 1
Diabetic Nephropathy and Management
Wandile, P. M. (2023) · Open Journal of Nephrology · doi:10.4236/ojneph.2023.133030 · Cited by 6
Hirai, T., & Katayama, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104272 · Cited by 1
Chang, T. I., Cluett, J., Cohen, D. L., Drawz, P. E., Hudson, J. Q., Kramer, H., Rahman, M., & Awdishu, L. (2026) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2026.07.006 · Cited by 1
Recent Update in Diabetic Nephropathy
Kim, N. H. (2015) · Korean Journal of Medicine · doi:10.3904/kjm.2015.89.3.265 · Cited by 1
Dual Blocking of the Renin Angiotensin System: A Settled Issue?
Caputo, J. (2013) · Journal of Hypertension Open Access · doi:10.4172/2167-1095.1000148 · Cited by 1
Heart and kidney disease: a cardiovascular high-risk constellation
Schunk, S. J., Speer, T., & Fliser, D. (2020) · Herz · doi:10.1007/s00059-020-05012-z · Cited by 1
Schmitt, R. (2021) · Der Nephrologe · doi:10.1007/s11560-021-00525-y · Cited by 1
Harbord, N. B., Winchester, J. F., Charen, E., Ornillo, C., Sheth, N., Feinfeld, D. A., & Dubrow, A. J. (2017) · Springer eBooks · doi:10.1007/978-3-319-20797-1_22-2 · Cited by 1
New modalities for treatment of diabetic nephropathy: a mini review
Momeni, A., Momeni, M., & Amiri, M. (2015) · International journal of epidemiologic research · Cited by 1
de Borst, M. H., & Navis, G. J. (2015) · Diabetes Management · doi:10.2217/dmt.15.12 · Cited by 1
Dual Therapy Difficulties in Angiotensin Blockade for Proteinuria
Hung, K. W., Blaine, J. T., & Faubel, S. G. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2014.3460 · Cited by 1
Current Therapeutic Approaches to Cardio-Protection in Hypertension
Parra, D., & Hough, A. R. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0457-5 · Cited by 1
Sanz, M. M. (2014) · Panorama actual del medicamento · Cited by 1
Peter Andrew McCullough, MD, MPH: An Interview With the Editor
McCullough, P. A., & Roberts, W. C. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.08.034 · Cited by 1
Self-citationNonglycemic Targets in Diabetes
DeWitt, D. E., Dugdale, D. C., & Adam, W. R. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.08.014 · Cited by 2
Diabetic Nephropathy Clinical Trials: A Critical Appraisal
Nahas, M. E., & Feldt‐Rasmussen, B. (2015) · Springer eBooks · doi:10.1007/978-3-319-10292-4_9 · Cited by 1
Managing hypertension in diabetes
Morris, D. (2015) · Independent Nurse · doi:10.12968/indn.2015.20.22 · Cited by 1
Abdul‐Rahim, A. H., Docherty, K. F., Skali, H., Køber, L., Dickstein, K., Maggioni, A. P., VIu, M., Zannad, F. M., Velazquez, E. J., Califf, R. M., et al. (2016) · European Stroke Journal · doi:10.1177/2396987316646025 · Cited by 1
Combined use of renin-angiotensin-aldosterone system-acting agents: a cross-sectional study
Farcas, A. M., Leucuta, D., Bucșa, C., Mogoșan, C., & Dumitrascu, D. L. (2016) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-016-0378-2 · Cited by 2
A glimpse of diabetic nephropathy.
Khoshjou, F. (2017) · Europe PMC (PubMed Central) · Cited by 1
Sun, B., Hu, S., Li, Y., Zhu, E., Li, L., Han, F., Li, C., & Chen, L. (2016) · Oncotarget · doi:10.18632/oncotarget.13127 · Cited by 1
RetractedDrug Discovery in Tissue Fibrosis
Pinto, S., Hoek, M., Huang, Y., Costet, P., Ma, L., & Imbriglio, J. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12432-1 · Cited by 2
Gupta, A., Narain, U., & Dabu, R. (2018) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20182135 · Cited by 1
Hypertension and Chronic Kidney Disease
Sternlicht, H., & Bakris, G. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00033-0 · Cited by 1
Alicic, R. Z., & Tuttle, K. R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00037-8 · Cited by 1
Test the Urine: Understanding Haematuria, Proteinuria and Urinary Infection
Rayner, H. C., Thomas, M. E., & Milford, D. V. (2020) · Springer eBooks · doi:10.1007/978-3-030-43027-6_12 · Cited by 1
Novel strategies of hypertension management in chronic kidney disease
Rysz, J., Banach, M., Franczyk, B., & Gluba-Brzózka, A. (2020) · Archives of Medical Science · doi:10.5114/aoms.2019.88020 · Cited by 1
Inflammatory Mechanisms in Diabetic Kidney Disease
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_32 · Cited by 1
Decarlini, M. F. (2017) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v20i2.6745 · Cited by 1
Treatment of Resistant Hypertension in Real Clinical Settings
Maltseva, A. S., Tsygankova, A. E., Габитова, М. А., Rodionov, A. V., & Fomin, V. V. (2021) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2021-04-03 · Cited by 1
Nigella sativa and prevention of nephrotoxicity: A comprehensive update
Akhter, R., Nazir, S., Rasool, S., Ovais, S., Wali, A. F., Jan, H., Alam, M. F., Rehman, M. U., & Rasool, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824462-3.00009-3 · Cited by 1
Putting it All Together: Practical Approach to the Patient with Diabetic Kidney Disease
Eng, E., & Quaggin, S. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_29 · Cited by 1
Rossing, P. R., & Persson, F. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.06.002 · Cited by 1
Marshall, S. M., & Flyvbjerg, A. (2016) · Wiley eBooks · doi:10.1002/9781118924853.ch39 · Cited by 1
Hemmstoffe des Renin-Angiotensin-Systems
Anlauf, M., & Weber, F. (2015) · Springer eBooks · doi:10.1007/978-3-662-47186-9_4 · Cited by 3
de Farias, M. E. B., Queiroz, D., & Victor, F. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_37 · Cited by 1
Copeland, L., & Gillis, K. A. (2020) · InnovAiT Education and inspiration for general practice · doi:10.1177/1755738019894027 · Cited by 1
Morales, E., Gutiérrez, E., Caro, J., Sevillano, Á., Rojas-Rivera, J. E., & Praga, M. (2015) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2015.11.007 · Cited by 1
Tesař, V., & Vachek, J. (2018) · Cor et Vasa · doi:10.1016/j.crvasa.2017.12.006 · Cited by 1
Prise en charge de la maladie rénale diabétique
(2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00012-9 · Cited by 1
Diabetic Kidney Disease: Identification, Prevention, and Treatment
Caramori, M. L., & Rossing, P. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-98927-9_7 · Cited by 1
Clinical Management of CKD: Prevention of Progression
Abdullah, S., Methven, S., & Tomson, C. (2022) · Springer eBooks · doi:10.1007/978-3-030-76419-7_67 · Cited by 1
IgA Nephropathy in Adults and Children
Yeo, S. C., Trimachi, H., & Barratt, J. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch17 · Cited by 1
Choice of Antihypertensive Drugs and Antihypertensive Drug Combination in Diabetes
Leung, A. A. C. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_24 · Cited by 2
Sourij, H., Edlinger, R., Prischl, F. C., Kaser, S., Horn, S., Antlanger, M., Paulweber, B., Aberer, F., Brix, J. M., Cejka, D., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-022-02147-3 · Cited by 1
Yamout, H., & Bakris, G. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00026-8 · Cited by 1
Siregar, R. S., Ramayani, O. R., Harris, D., Lelo, A., Jusuf, N. K., Eyanoer, P. C., Rusda, M., & Amin, M. M. (2023) · Medical Archives · doi:10.5455/medarh.2023.77.422-427 · Cited by 1
Finerenone: A Novel Drug Discovery for the Treatment of Chronic Kidney Disease
Rana, A., & Sahu, J. K. (2024) · Current Drug Discovery Technologies · doi:10.2174/0115701638283354240103115420 · Cited by 2
Николаевна, С. О. (2024) · Kazan medical journal · doi:10.17816/kmj626252 · Cited by 1
Ураження нирок при артеріальній гіпертензії (діагностичні й терапевтичні аспекти)
Koval, S. M., Рєзнік, Л. А., Старченко, Т. Г., & Литвинова, О. М. (2025) · HYPERTENSION · doi:10.22141/2224-1485.17.4.2024.369 · Cited by 1
Approach to Chronic Kidney Disease in the Diabetic Patient
Afshinnia, F., & Brosius, F. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00043-3 · Cited by 1
FDA Approved pediatric antihypertensive agents
Doshi, A. S. (2014) · Digital Commons@Becker (Washington University School of Medicine) · Cited by 1
RAAS Blockade as First-Line Antihypertensive Therapy among People with CKD
Georgianos, P. I., Balaskas, E. V., & Zebekakis, P. E. (2017) · InTech eBooks · doi:10.5772/66180 · Cited by 1
Diabetes and Chronic Kidney Disease: Concern, Confusion, Clarity?
Senior, P. A. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.08.001 · Cited by 1
Is dual RAAS blockade useful in diabetic nephropathy?
(GrAM), G. D. A. M., Wu, M. A., & Perego, F. (2014) · Internal and Emergency Medicine · doi:10.1007/s11739-014-1075-6 · Cited by 1
Standard and novel therapeutic approaches to diabetic nephropathy
Egido, J., Fernández‐Fernández, B., Ortíz, A., Mas, S., & Gómez‐Guerrero, C. (2015) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 1
Mohammed‐Ali, Z. (2017) · MacSphere (McMaster University) · doi:10.71548/9405 · Cited by 1
Salam, A., & Rodgers, A. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13522 · Cited by 1
Mauricio, S. J. (2011) · Chalmers Publication Library (Chalmers University of Technology) · Cited by 1
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?
Tan, S. K., & Cooper, M. E. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2277762 · Cited by 1
Hypertension in Diabetes Mellitus
Elliott, W. J. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0793-9_10
Proteinurie und Blocker des Renin-Angiotensin-Aldosteron-Systems
Lindner, T. H. (2013) · Der Diabetologe · doi:10.1007/s11428-013-1089-0
Floege, J. (2014) · Der Nephrologe · doi:10.1007/s11560-013-0853-x
Sintado, L., Renal, U., & Durand, C. G. (2014) · DOAJ (DOAJ: Directory of Open Access Journals)
High-impact session from kidney week
Kirk, R. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.236
Treatment of Nephrotic Syndrome: Retrospection
Yee, J. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.01.012
Sudden Cardiac Death and Arrhythmia in CKD
Martin, S. P., & Parfrey, P. S. (2014) · Springer eBooks · doi:10.1007/978-3-319-09162-4_3
Böhlke, M. (2015) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944715592819
59-Year-Old Man With Aphasia and Proteinuria
Lyle, M. A., Seaburg, L., & Bhagra, A. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.11.017
Advani, A. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.05.005
The Lipid independent Effect of Statins on Albuminuria in Type-2 Diabetes Mellitus
Rubio-Guerra, A. F., Vargas‐Robles, H., Vargas‐Ayala, G., López, L. R., Elizalde-Barrera, C. I., & Escalante-Acosta, B. A. (2014)
Treatment of Hypertension in Patients with Chronic Kidney Disease
Aronow, W. S. (2014)
Professional Ethics in Biomedical Science: from Open Access to Conflict of Interest
Pontremoli, R. (2015) · Giornale di Techniche Nefrologiche e Dialitiche · doi:10.5301/gtnd.2015.15070
Ischemic Tolerance in Uremic Rabbits
Kingma, J. G., Sénéchal, G., Rouleau, J. R., & Kingma, I. (2015) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2015.512041
Dual therapy and diabetic kidney disease
Desai, T. (2015) · Indian Journal of Nephrology · doi:10.4103/0971-4065.168441
Puhakainen, M. (2015) · Jyväskylä University Digital Archive (University of Jyväskylä)
Metadata
- Authors
- Fried, L. F., Emanuele, N., Zhang, J. H., Brophy, M., Conner, T. A., Duckworth, W., Leehey, D. J., McCullough, P. A., O'Connor, T., Palevsky, P. M., Reilly, R. F., Seliger, S. L., Warren, S. R., Watnick, S., Peduzzi, P., & Guarino, P.
- Affiliations
- Boston University (US)
- Loyola University Medical Center (US)
- VA Connecticut Healthcare System (US)
- University of New Mexico (US)
- University of Arizona (US)
- Ascension (US)
- University of Pittsburgh (US)
- VA North Texas Health Care System (US)
- University of Maryland, Baltimore (US)
- Portland VA Medical Center (US)
- Yale University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-11-14
- Volume
- 369
- Issue
- 20
- Pages
- 1892-1903
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2162368776
- Semantic Scholar
- 7e191f2ee9fe17b31623d78bf58b03d157e94654
- Cited by
- 1,169
- References
- 19
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 67 · 2023: 95 · 2022: 75 · 2021: 102 · 2020: 89 · 2019: 105 · 2018: 88 · 2017: 98 · 2016: 104 · 2015: 123 · 2014: 122 · 2013: 9
- FWCI
- 90.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- diabetic nephropathy, losartan, lisinopril, ACE inhibitors, angiotensin receptor blockers, type 2 diabetes, estimated glomerular filtration rate decline, end-stage renal disease, albuminuria, hyperkalemia, acute kidney injury, drug safety, early trial termination, cardiovascular events, mortality, proteinuria, kidney disease progression
- MeSH terms
- Adult, Angiotensin-Converting Enzyme Inhibitors, Diabetic Nephropathies, Double-Blind Method, Drug Therapy, Combination, Female, Glomerular Filtration Rate, Humans, Kidney Failure, Chronic, Male, Middle Aged, Lisinopril, Losartan, Angiotensin II Type 1 Receptor Blockers, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.